RANI
NASDAQ
$0.69
Rani Therapeutics Holdings Inc Class A (RANI)
Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the oral administration of biologic therapeutics. This groundbreaking approach not only enhances patient adherence but also aligns with the growing preference for non-invasive treatment options. With a robust and diversified pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned for significant growth. The company’s commitment to cutting-edge research and development, along with key partnerships, further underscores its potential to make impactful advancements in the pharmaceutical sector.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $7.50 (+992.82%)
Market Cap
$122M
Revenue 5Y CAGR
+21.08%
Free Cash Flow Yield
-14.04%
Beta (5Y)
2.23
Price Chart
Valuation
Market Cap$122M
P/S29.37
P/B2.54
Profitability
Total Revenue (TTM)$3.17M
Gross Profit (TTM)$3.17M
EBITDA-$34M
Operating Margin-488.2%
EPS-$0.56
Financial Health
Free Cash Flow Yield-14.04%
Growth & Risk
Revenue 5Y CAGR+21.08%
Beta (5Y)2.23
Sharpe Ratio0.83